Brief: Granules India Says Granules Pharmaceuticals Completes USFDA Postmarketing Adverse Drug Experience Inspection With 0 Observations
04/08/2023 03:55
Aug 4 (Reuters) - Granules India Ltd GRAN.NS :
* GRANULES PHARMACEUTICALS, INC. COMPLETES USFDA
POSTMARKETING
ADVERSE DRUG EXPERIENCE INSPECTION WITH 0 OBSERVATIONS
Source text for Eikon: ID:
Further company coverage: GRAN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Granules India
See all newsGranules India profit surges as higher sales outweigh cost pressures
Brief: Granules India Q2 Consol Profit 1.82 Billion Rupees
Brief: Granules Says Incorporated Wholly Owned Subsidiary Triton Farmaceutica S.A. De C.V. In Mexico
Brief: Granules Promoter Group Pays 10.93 Billion Rupees For Preferential Issue
Granules India falls after key shareholder trims stake